# RSV Vaccination to Reduce Recurrent AECOPD

> **NCT07508644** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 320 (estimated)

## Conditions studied

- COPD
- RSV

## Interventions

- **BIOLOGICAL:** RSV vaccination (Arexvy, GlaxoSmithKline)

## Key facts

- **NCT ID:** NCT07508644
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-07-01
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07508644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07508644, "RSV Vaccination to Reduce Recurrent AECOPD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07508644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*